- Home
- VTYX vs MPV Comparison
VTYX vs MPV Comparison
Compare VTYX & MPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- MPV
- Stock Information
- Founded
- VTYX 2018
- MPV 1988
- Country
- VTYX United States
- MPV United States
- Employees
- VTYX N/A
- MPV N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- MPV Finance Companies
- Sector
- VTYX Health Care
- MPV Finance
- Exchange
- VTYX Nasdaq
- MPV Nasdaq
- Market Cap
- VTYX 184.6M
- MPV 181.3M
- IPO Year
- VTYX 2021
- MPV N/A
- Fundamental
- Price
- VTYX $2.30
- MPV $17.30
- Analyst Decision
- VTYX Buy
- MPV
- Analyst Count
- VTYX 5
- MPV 0
- Target Price
- VTYX $8.40
- MPV N/A
- AVG Volume (30 Days)
- VTYX 2.3M
- MPV 25.2K
- Earning Date
- VTYX 11-07-2024
- MPV 01-01-0001
- Dividend Yield
- VTYX N/A
- MPV 8.71%
- EPS Growth
- VTYX N/A
- MPV N/A
- EPS
- VTYX N/A
- MPV 1.71
- Revenue
- VTYX N/A
- MPV N/A
- Revenue This Year
- VTYX N/A
- MPV N/A
- Revenue Next Year
- VTYX N/A
- MPV N/A
- P/E Ratio
- VTYX N/A
- MPV $9.35
- Revenue Growth
- VTYX N/A
- MPV N/A
- 52 Week Low
- VTYX $1.67
- MPV $11.18
- 52 Week High
- VTYX $11.48
- MPV $16.42
- Technical
- Relative Strength Index (RSI)
- VTYX 47.68
- MPV 62.20
- Support Level
- VTYX $2.21
- MPV $17.05
- Resistance Level
- VTYX $2.54
- MPV $17.22
- Average True Range (ATR)
- VTYX 0.27
- MPV 0.16
- MACD
- VTYX -0.05
- MPV 0.02
- Stochastic Oscillator
- VTYX 8.02
- MPV 88.17
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About MPV Barings Participation Investors
Barings Participation Investors is a diversified closed-ended management investment company. The Trust's investment objective is to maintain a portfolio of securities providing a current yield and an opportunity for capital gains. Its principal investments are privately placed, below-investment grade, long-term debt obligations including bank loans and mezzanine debt instruments. The company invests in various sectors such as aerospace and defense; automotive; building materials; consumer products and others.